Sprycel — Total Revenues
Bristol-Myers Squibb Sprycel — Total Revenues decreased by 0.8% to $119.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 59.0%, from $290.00M to $119.00M. Over 3 years (FY 2021 to FY 2024), Sprycel — Total Revenues shows a downward trend with a -15.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful patient retention, while a decrease may signal increased competition from generics or a shift in clinical treatment standards.
Detailed definition
This metric represents the total global net sales generated from the pharmaceutical product Sprycel, a tyrosine kinase i...
Peer comparison
Similar to revenue metrics for mature, branded oncology assets at other large-cap pharmaceutical companies, where performance is often evaluated based on patent expiration timelines and market share retention.
bmy_segment_sprycel_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $541.00M | $551.00M | $555.00M | $483.00M | $544.00M | $560.00M | $578.00M | $429.00M | $458.00M | $517.00M | $526.00M | $374.00M | $424.00M | $290.00M | $198.00M | $175.00M | $120.00M | $119.00M |
| QoQ Change | — | +1.8% | +0.7% | -13.0% | +12.6% | +2.9% | +3.2% | -25.8% | +6.8% | +12.9% | +1.7% | -28.9% | +13.4% | -31.6% | -31.7% | -11.6% | -31.4% | -0.8% |
| YoY Change | — | — | — | — | +0.6% | +1.6% | +4.1% | -11.2% | -15.8% | -7.7% | -9.0% | -12.8% | -7.4% | -43.9% | -62.4% | -53.2% | -71.7% | -59.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's sprycel — total revenues?
- Bristol-Myers Squibb (BMY) reported sprycel — total revenues of $119.00M in Q3 2025.
- How has Bristol-Myers Squibb's sprycel — total revenues changed year-over-year?
- Bristol-Myers Squibb's sprycel — total revenues decreased by 59.0% year-over-year, from $290.00M to $119.00M.
- What is the long-term trend for Bristol-Myers Squibb's sprycel — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's sprycel — total revenues has grown at a -15.3% compound annual growth rate (CAGR), from $2.12B to $1.29B.
- What does sprycel — total revenues mean?
- The total revenue generated from sales of the oncology drug Sprycel.